Acute ischemic stroke caused by loss of normal blood supply to the brain is a leading cause of long-term disability. Without proper diagnosis and treatment, acute ischemic stroke could result in permanent paralysis or death. The effects of a stroke will be determined by the location and extent of the brain damage and time to restoration of blood supply to the affected region. Treatment options include agents (e.g., tPA, alteplase) that can dissolve clots in the bloodstream and endovascular procedures such as thrombectomy.
In routine clinical practice, an accurate evaluation and follow-up of acute ischemic stroke are conducted using diagnostic imaging. CT and MRI are routinely employed. Evaluation of novel stroke treatments and procedures as part of a clinical study requires detailed planning of all the imaging visits required to assess, treat, and follow up with patients. The imaging schedule provides an outline of the appropriateness and timing of the imaging modalities needed to assess the safety and efficacy of the treatment. Imaging-based endpoints, such as the degree of recanalization and revascularization, have been shown to have a direct correlation with clinical outcomes.
During this presentation, Dr. Mayank Goyal will provide attendees with an overview of the imaging modalities for the evaluation of acute ischemic stroke along with the timing of the imaging. Dr. Goyal will also provide his thoughts on the imaging-based endpoints that are suitable to evaluate treatment efficacy. The presentation will be followed by a panel discussion between Ryan Bouchard (Vastrax) and Dr. Goyal that will further address the role of imaging in acute ischemic stroke studies.
Register for this webinar to learn about the various modalities of acute ischemic stroke imaging and how to choose the most appropriate imaging-based endpoints for trials.
Mayank Goyal, MD, Professor of Radiology and Clinical Neurosciences, University of Calgary; Director of Imaging and Endovascular Treatment at the Calgary Stroke Program
Dr. Goyal is a Professor in the Department of Radiology and Clinical Neurosciences at the University of Calgary and also the Director of Imaging and Endovascular treatment at the Calgary Stroke Program. Dr. Goyal’s passion and main research interest are acute stroke imaging, workflow, and intervention. Dr. Goyal is world-renowned for his groundbreaking work in efficiency and workflow in acute stroke intervention, including over 200 publications in peer-reviewed journals.
With the success of ESCAPE and SWIFT PRIME, Dr. Goyal has been an integral part of changing stroke care across the world and helping thousands of patients have a good outcome from what is an otherwise devastating disease.
He is also leading a meta-analysis (HERMES) consisting of the recent 7 positive trials published in NEJM. Dr. Goyal continues to push the boundaries of stroke research and is the Co-PI for the ESCAPE-NA1 trial (partially funded by CIHR) testing the added usefulness of neuroprotection in addition to endovascular stroke therapy and co-PI of a worldwide study of understanding variance of decision making in acute stroke (UNMASK EVT).Message Presenter
Ryan Bouchard, President, Vastrax
Ryan Bouchard has been leading Vastrax since its founding in 2018. As President of the company, he provides the vision, leadership, strategy, and management to the organization with a focus on making Vastrax the partner of choice for vascular development programs.
Prior to Vastrax, Ryan spent 18 years working in the medical device and product engineering fields and led Ora’s Medical Devices division from 2010 to 2020. He has been involved in numerous MedTech regulatory approvals and product launches globally.
He earned a Master of Business Administration, General Management, at the Kellogg School of Management at Northwestern University in Illinois, and a Bachelor of Science in Physics and Mathematics from Bates College in Maine.Message Presenter
Who Should Attend?
This webinar will be of interest to medical device and drug companies innovating in acute ischemic stroke treatment or the broader neurovascular space, including site investigators and academic centers (as applicable).
What You Will Learn
In this webinar, attendees will learn about:
- The primary role of imaging in acute ischemic stroke
- The appropriate time points and modalities needed to determine the safety and efficacy of treatment
- Recommendations for an imaging-based assessment panel to evaluate the treatment outcomes
- Recommendations on the radiologist paradigm and FDA-accepted standards for independent image review
Medical Metrics Inc.
Medical Metrics Inc. (MMI) is an experienced provider of medical imaging core laboratory services for multicenter clinical trials. MMI’s ISO 9001-certified services include imaging protocol development, medical image management, independent image review, and scientific consulting. With 20+ years of experience on hundreds of studies, MMI can support global trials ranging from early-phase feasibility to post-market surveillance across a range of therapeutic areas, including neurology, orthopedics, spine, cardiology, vascular and surgical interventions, ENT, and AI/ML technologies.
Vastrax, LLC, Vastrax is the global development hub to support therapeutic innovators in the areas of neurovascular and peripheral products. The Vastrax team possesses a combined 35+ years of clinical, commercial, and regulatory experience in the development of these products. Their deep knowledge has put them at the forefront of new technologies in working to aid patients by efficiently bringing leading-edge products to market.
Their operational models are focused solely on the vascular space, providing the insights and methods needed to support complex product development. Over the years, Vastrax’s team of experts has demonstrated repeated editorial success among the landmark publications that aid in the advancement of treatments across a wide range of vascular diseases. These experts have also served as key innovators whose novel technologies have transformed the overall standard of care.